In the crowded landscape of neuroscience, Axonis Therapeutics isn't chasing a dozen targets—they're doubling down on a single, critical ion transporter called KCC2. This isn't a spray-and-pray approach; it's a high-stakes wager that restoring functional inhibition in the brain is the key to treating devastating neurological disorders.

"Axonis isn't building a platform company—they're building a precision strike force for KCC2."

The leadership team reads like a biotech startup dream team. CEO Joanna Stanicka brings the strategic vision, while Chief Scientific Officer Shane Hegarty provides the scientific rigor. The presence of two Chief Staff roles (Eilah Berlow and Tiasha Shafiq) suggests an organization optimizing for execution speed—critical in drug development where timelines are measured in years, not quarters.

• Single-target focus on KCC2 creates clear differentiation but concentrates risk
• 32-person team suggests lean, capital-efficient operations
• 47% direct traffic indicates strong brand recognition among specialized audience
• WordPress + Tailwind stack shows pragmatic tech choices, not over-engineering